Published in Hepatitis Weekly, January 15th, 2007
The phase Ia trial will assess safety, tolerability, pharmacokinetics, and food affect in a double-blind, placebo-controlled, single-ascending-dose study. The study is being conducted at 1 clinical trial site in Europe and will enroll approximately 74 healthy volunteers. InterMune expects to dose the first patient with ITMN-191 sometime in early January...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.